Akers Biosciences, Inc. Directors Dealing (9389K)
January 06 2016 - 1:00AM
UK Regulatory
TIDMAKR
RNS Number : 9389K
Akers Biosciences, Inc.
06 January 2016
Akers Biosciences, Inc.
Directors Dealing
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company"), a leading designer and manufacturer of rapid diagnostic
screening and testing products, announces that Leslie Akers, the
wife of Raymond F. Akers, Jr. PhD, Co-founder and Executive
Chairman of the Company, has today purchased 2,100 ordinary shares
of no par value ("Ordinary Shares") at a price of $1.34 per
Ordinary Share (the "Purchase").
As a result of the Purchase, Dr. Akers' shareholding has
increased to 72,100 Ordinary Shares comprising 70,000 shares held
in the Akers Family Trust of which his wife is a trustee and 2,100
pursuant to the Purchase mentioned above. This represents 1.33% of
the total voting rights of the Company.
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSLLFEALAIEIIR
(END) Dow Jones Newswires
January 06, 2016 02:00 ET (07:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Oct 2023 to Oct 2024